SG11201908911QA - Modified mri contrast agents and uses thereof - Google Patents
Modified mri contrast agents and uses thereofInfo
- Publication number
- SG11201908911QA SG11201908911QA SG11201908911QA SG11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- san diego
- contrast agents
- mri contrast
- Prior art date
Links
- 239000002616 MRI contrast agent Substances 0.000 title abstract 5
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 244000113945 Pinus torreyana Species 0.000 abstract 1
- 235000006235 Pinus torreyana Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491159P | 2017-04-27 | 2017-04-27 | |
| PCT/US2018/029271 WO2018200615A2 (en) | 2017-04-27 | 2018-04-25 | Modified mri contrast agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908911QA true SG11201908911QA (en) | 2019-11-28 |
Family
ID=63920047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908911Q SG11201908911QA (en) | 2017-04-27 | 2018-04-25 | Modified mri contrast agents and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200046859A1 (https=) |
| EP (1) | EP3615088A4 (https=) |
| JP (1) | JP2020517584A (https=) |
| KR (1) | KR20190135500A (https=) |
| CN (1) | CN110582306A (https=) |
| AU (1) | AU2018258345A1 (https=) |
| CA (1) | CA3057976A1 (https=) |
| SG (1) | SG11201908911QA (https=) |
| WO (1) | WO2018200615A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2998528A1 (en) * | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4011684A1 (de) * | 1990-04-06 | 1991-10-10 | Schering Ag | Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung |
| JP3404787B2 (ja) * | 1993-03-12 | 2003-05-12 | 三菱ウェルファーマ株式会社 | 新規ジエチレントリアミンペンタ酢酸誘導体、該誘導体と金属原子との錯化合物、及び該錯化合物を含む診断剤 |
| AU726914B2 (en) * | 1996-04-01 | 2000-11-23 | Epix Pharmaceuticals, Inc. | Bioactivated diagnostic imaging contrast agents |
| DE19652387A1 (de) * | 1996-12-04 | 1998-06-10 | Schering Ag | Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung |
| US20030021750A1 (en) * | 2001-04-04 | 2003-01-30 | Bakan Douglas A. | Novel functional agents for magnetic resonance imaging |
| JP5291930B2 (ja) * | 2005-03-09 | 2013-09-18 | 独立行政法人科学技術振興機構 | 錯化合物及びそれから成るｍｒｉプローブ |
| WO2008144728A1 (en) * | 2007-05-21 | 2008-11-27 | Bracco Imaging S.P.A. | Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications |
-
2018
- 2018-04-25 US US16/492,660 patent/US20200046859A1/en not_active Abandoned
- 2018-04-25 KR KR1020197031523A patent/KR20190135500A/ko not_active Ceased
- 2018-04-25 EP EP18791343.9A patent/EP3615088A4/en not_active Withdrawn
- 2018-04-25 AU AU2018258345A patent/AU2018258345A1/en not_active Abandoned
- 2018-04-25 JP JP2019553045A patent/JP2020517584A/ja active Pending
- 2018-04-25 CN CN201880027317.0A patent/CN110582306A/zh active Pending
- 2018-04-25 WO PCT/US2018/029271 patent/WO2018200615A2/en not_active Ceased
- 2018-04-25 SG SG11201908911Q patent/SG11201908911QA/en unknown
- 2018-04-25 CA CA3057976A patent/CA3057976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN110582306A (zh) | 2019-12-17 |
| WO2018200615A3 (en) | 2019-01-10 |
| EP3615088A4 (en) | 2021-01-27 |
| CA3057976A1 (en) | 2018-11-01 |
| US20200046859A1 (en) | 2020-02-13 |
| KR20190135500A (ko) | 2019-12-06 |
| EP3615088A2 (en) | 2020-03-04 |
| AU2018258345A1 (en) | 2019-10-17 |
| JP2020517584A (ja) | 2020-06-18 |
| WO2018200615A2 (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807025SA (en) | Crispr/cas systems for c-1 fixing bacteria | |
| SG11201811643TA (en) | Compounds and methods for modulating rna function | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
| SG11201804412SA (en) | Dimeric contrast agents | |
| SG11201906973TA (en) | Multiple transgene recombinant adenovirus | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |